Cellipont Bioservices
Denise Krohn has a diverse work experience in various roles related to quality assurance and regulatory compliance. Denise is currently working as the SVP of Quality & Regulatory at Cellipont Bioservices since 2022. Before that, they worked as the Vice President of Quality at Catalent Cell and Gene Therapy from 2019 to 2021. In this role, they were responsible for establishing the Site Quality Plan, managing client relationships, and providing strategic direction on quality compliance and operations.
Prior to their role at Catalent, Denise held positions at Paragon Bioservices, Inc. as the Vice President of Quality Assurance and Compliance from 2019 to 2021, and as the Sr. Director of Quality Assurance from 2017 to 2019. Denise also worked at NOVAVAX INC as the Sr. Director of QA Compliance and Development from 2014 to 2017, and as the Associate Director of Quality Assurance Development and Compliance from 2013 to 2014.
Denise's earlier work experience includes roles at WuXi AppTec as the Director of Quality Assurance in 2012, and at Shire Pharmaceuticals, Inc. where they held various positions such as Associate Director of Quality Assurance - Value Stream Leader from 2010 to 2011, Manager of Quality Assurance - Value Stream Leader from 2009 to 2010, Manager of Quality Assurance-Quality Improvement from 2006 to 2009, and Senior Quality Engineer and Supervisor of Quality Assurance from 2003 to 2006.
Denise began their career at Atlantic Pharmaceutical Services, Inc. as a Technician in Quality Assurance from 1999 to 2001, and later worked as a Project Coordinator in Quality Assurance from 2001 to 2003.
Overall, Denise Krohn has extensive experience in quality assurance and regulatory compliance, with a focus on strategic planning, client management, and process improvement.
Denise Krohn obtained a Bachelor of Science degree in Biology from Millersville University of Pennsylvania from 1994 to 1998.
This person is not in any offices
Cellipont Bioservices
Cellipont Bioservices is a cell therapy CDMO with more than 15 years’ experience in the development and small-to-large batch manufacturing of cell therapies. Our leaders have played an instrumental role in shaping cell therapy development and manufacturing methods and technologies, and our technically-strong team has been recognized by customers and technology partners for its ability to productively grow challenging cells. Cellipont is driven to help our clients to expand patient access to life-changing medicines through best-in-class development, analytical and manufacturing capabilities. We are a small company with a culture that is extremely responsive and customer-centric. Despite our size, Cellipont Bioservices has very deep technical experience, including 18,000+ tissue samples and more than 900 primary cell cultures. With decades of experience at advanced therapy service companies large and small, our leadership team is guiding Cellipont’s growth with deep knowledge of what it takes succeed in this space. Cellipont Bioservices facilities and quality systems are GMP-compliant and we hold a California Food & Drug Branch manufacturing license. We have extensive experience in multiple product areas, including CAR-T, iNK, dendritic cell, & other novel cell therapy approaches. OUR NAME: By combining “cell” with the latin root for bridge (pont), the name Cellipont Bioservices reflects several dimensions of what we are all about: we bridge our innovator clients with patients; we bridge technical excellence and personal service; and for our team, we bridge personal passion with professional vocation. As we finalize our corporate rebranding, we look forward to launching a new website in the coming weeks to better share our vision with you.